K7M2 / K7M2-luc Orthotopic Mouse Model Service for Sarcoma

The K7M2 / K7M2-luc orthotopic mouse model is the benchmark syngeneic osteosarcoma platform, implanting a highly metastatic murine bone-tumor line directly into the tibial marrow cavity of immunocompetent BALB/c mice to recreate primary bone sarcoma growth and its near-obligatory spread to the lungs. Alfa Cytology provides this model as a complete preclinical package — authenticated cell banking, precision intratibial surgery, serial luciferase imaging of primary tumors and pulmonary metastases, therapeutic intervention including immunotherapies, and terminal histopathology — so sponsors gain a demanding metastasis model without developing microsurgical and imaging capabilities in-house.

Overview of K7M2 / K7M2-luc Orthotopic Mouse Model for Sarcoma

K7M2 is a murine osteosarcoma cell line with one of the most instructive pedigrees in preclinical bone cancer research. Its ancestor, K7, was among the first metastatic osteosarcoma lines ever established, derived from a tumor that arose spontaneously in an aged female BALB/c mouse. The K7M2 (wild-type) line was created by Khanna and colleagues in 2000 through deliberate in vivo selection: K7 cells were injected into the proximal tibia, the resulting lung metastases were harvested and re-implanted into tibial sites, and this cycle was repeated until a ferociously aggressive derivative emerged. The result is a bone-lineage osteoblast-type cell (expressing bone sialoprotein, osteopontin, decorin, biglycan, and ezrin, with CD31 positivity) that forms primary tumors with better than 95% take rates in syngeneic BALB/c hosts and seeds pulmonary metastases in over 90% of animals — against 33% for its intermediate sister line K12 and essentially zero for the parental K7. Histology of both primary tumors and lung lesions mirrors human osteosarcoma, and the model's high angiogenic index and ezrin-driven metastatic biology have made it a reference system for dissecting the spread of bone sarcoma.

Fig 1. Weekly IVIS imaging of orthotopic K7M2-Luc tibial tumors at 0.3×10⁶ and 1×10⁶ cell doses (weeks 1–3), with μCT and H&E showing tumor invasion into the tibial marrow cavity. (Freeman, Fiona E., et al., 2023)

Orthotopically, K7M2 is most often implanted by intratibial injection of a concentrated cell suspension — classically 1 × 10⁶ cells in 25 μL — into the marrow cavity of the proximal tibia, a technique that places tumor cells in contact with bone, marrow stroma, and the remodeling microenvironment from which osteosarcoma naturally arises. Primary tibial tumors become palpable within roughly two weeks, after which pulmonary dissemination accelerates, and a widely used study design couples orthotopic growth with palliative limb amputation once tumors reach a defined volume so that anti-metastatic therapies can be tested against established lung disease. The luciferase-tagged derivative, K7M2-luc, enables quantitative bioluminescence tracking of both the primary lesion and lung burden on IVIS-class imagers, sharpening the detection of metastatic foci and response kinetics. Because the model runs in immunocompetent BALB/c mice with an intact immune compartment — and shows high immune-cell infiltration and responsiveness to combination immunotherapy while being largely refractory to PD-1 blockade alone — it has become a preferred proving ground for checkpoint combinations, cytokine therapies, and anti-metastatic strategies in sarcoma research.

Cell Line Information: K7M2 / K7M2-luc

K7M2 wt is distributed by the American Type Culture Collection (ATCC CRL-2836); ATCC additionally banks the plasmid-bearing derivative K7M2-pCI Neo (CRL-2837). The luciferase-tagged variant used for optical tracking, K7M2-luc, is generated by stable transfection of a luciferase expression construct and retains the parental take rates and metastatic behavior. Core characteristics are compiled below.

Our Services

With Alfa Cytology as your partner, the K7M2 / K7M2-luc orthotopic osteosarcoma study runs as one integrated program: authenticated, low-passage cell banks are prepared and luciferase-verified, syngeneic BALB/c hosts are acclimated, concentrated inocula are delivered into the tibial marrow cavity by experienced microsurgeons, primary tumors and lung metastases are tracked on schedule by bioluminescence imaging, and your treatment arms — from cytotoxics to checkpoint combinations and cytokine therapies — are executed through terminal histopathology under IACUC-compliant conditions, with all results consolidated into an audit-ready data package.

Workflow of K7M2 / K7M2-luc Orthotopic Mouse Model Construction

Orthotopic osteosarcoma modeling hinges on three skills: disciplined culture of the metastatic line, precise intratibial microsurgery, and quantitative imaging of disseminated disease. A standard engagement proceeds as follows.

1. Cell preparation and quality control: K7M2 or K7M2-luc cells are expanded at low passage, confirmed mycoplasma-free, and luciferase activity validated in vitro; the inoculum is concentrated to the standard 1 × 10⁶ cells in 25 μL PBS shortly before surgery.
2. Host selection and acclimation: Male or female BALB/c mice, typically 6–10 weeks of age, are quarantined and acclimated in a specific-pathogen-free barrier facility before the procedure.
3. Anesthesia and surgical access to the tibia: Under isoflurane anesthesia, the proximal tibia is exposed through a small longitudinal skin incision, and the knee joint is flexed to position the tibial plateau for marrow-cavity access.
4. Intratibial inoculation: A fine-gauge needle is advanced through the tibial plateau into the marrow cavity, and the 25 μL cell suspension is injected slowly; the injected limb is typically the hind limb, with care taken to prevent reflux along the needle track.
5. Closure and postoperative management: The skin is closed with sutures or wound clips, analgesia is administered, and mice recover with daily monitoring of weight, gait, and incision integrity.
6. Primary tumor monitoring and imaging: Palpation and caliper measurement track the tibial tumor from approximately two weeks post-implantation, while bioluminescence imaging after intraperitoneal D-luciferin injection provides quantitative readouts of primary tumor and early pulmonary signal.
7. Randomization, intervention, and amputation option: Mice are randomized into treatment arms at a defined tumor volume; where the study targets metastatic disease, the affected limb is amputated at the preset threshold (for example near 450 mm³) so that therapies are tested against established lung metastases.
8. Endpoint analysis and reporting: At termination, primary tumors, lungs, and other organs are resected; metastatic nodules are enumerated and weighed, lungs undergo H&E staining and immunohistochemistry (including CD31/angiogenesis and ezrin panels), imaging signals are cross-referenced with histology, and all data are consolidated into the final report.

Fig 2. K7M2 / K7M2-luc orthotopic mouse model construction workflow.

Case Study-K7M2 / K7M2-luc Orthotopic Mouse Model Development

Alfa Cytology has applied the K7M2 / K7M2-luc orthotopic platform across preclinical programs addressing cytotoxic regimens, targeted agents, and immunotherapy combinations in osteosarcoma, including amputation-based anti-metastatic study designs in which therapies are evaluated against established pulmonary disease. In these engagements, serial bioluminescence imaging quantified primary tumor growth and lung metastatic burden in individual animals, while terminal lung histology and immunohistochemical panels completed the pharmacological assessment. Study parameters such as inoculum format, randomization thresholds, amputation criteria, and endpoint panels are configured to order. Case materials can be shared under confidentiality agreements upon request.

Why Choose Alfa Cytology?

The K7M2 orthotopic model punishes imprecision: marrow-cavity technique, imaging discipline, and metastasis-pathology expertise must all be present for trustworthy data. Alfa Cytology fields all three in-house, making the K7M2 / K7M2-luc orthotopic model a dependable instrument for your sarcoma program.

• Mastery of the intratibial technique, with high take rates and minimized perioperative loss.
• Quantitative bioluminescence imaging tracking both primary tibial tumors and pulmonary metastases in the same animal.
• Genuine immunocompetent syngeneic system for immunotherapy, checkpoint-combination, and cytokine studies.
• Established amputation-based anti-metastatic designs mirroring the clinical adjuvant setting.
• Authenticated bone-lineage biology, including ezrin and angiogenesis panels validated against histology.
• Configurable study parameters, from inoculum dose to randomization and amputation thresholds.
• IACUC-compliant, documentation-rich operations delivering audit-ready records at every stage.

Contact Us

If your sarcoma program needs a metastasis-capable orthotopic platform, contact us today to discuss K7M2 / K7M2-luc study design, imaging cadence, and anti-metastatic endpoints with our scientific team. Reach out for a confidential consultation and project quotation — Alfa Cytology is ready to advance your next preclinical study.

For research use only. Not intended for any clinical use.